Glenmark is set to initiate a Phase I study for its inhibitor of immuno-oncology target hematopoietic progenitor kinase 1 (HPK1), a segment that has seen increased activity over the recent past with BeiGene, Nimbus and Treadwell Therapeutics among those advancing their molecules.

MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.

The US places certain limits on the use of GSK's Xevudy, while Canada signs a supply deal for another antibody therapy, AstraZeneca's Evusheld. Meanwhile, Novavax starts EU shipments of its vaccine and the UK funds ConserV's pan-coronavirus vaccine.  

Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.